Abstract | BACKGROUND AND OBJECTIVE: METHODS: We conducted a retrospective target trial emulation using Swedish pre-existing data. We searched for eligible participants who were dispensed methotrexate or azathioprine in the Prescribed Drug Register (PDR) every day between January 2007 and June 2013. Adults were eligible if they had ≥2 ICD-coded visits for sarcoidosis in the National Patient Register (NPR) and were dispensed ≥1 systemic corticosteroid but no methotrexate or azathioprine in the past 6 months (PDR). Within 6 months of methotrexate or azathioprine initiation, diagnosis of infectious disease was identified (visit in the NPR where infectious disease was the primary diagnosis). We estimated RR and risk differences comparing methotrexate (n = 667) to azathioprine initiations (n = 259) using targeted maximum likelihood estimation (TMLE) adjusting for demographic factors, comorbidity and sarcoidosis severity proxies. RESULTS: CONCLUSION:
|
Authors | Marios Rossides, Susanna Kullberg, Daniela Di Giuseppe, Anders Eklund, Johan Grunewald, Johan Askling, Elizabeth V Arkema |
Journal | Respirology (Carlton, Vic.)
(Respirology)
Vol. 26
Issue 5
Pg. 452-460
(05 2021)
ISSN: 1440-1843 [Electronic] Australia |
PMID | 33398914
(Publication Type: Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Copyright | © 2021 The Authors. Respirology published by John Wiley & Sons Australia, Ltd on behalf of Asian Pacific Society of Respirology. |
Chemical References |
- Immunosuppressive Agents
- Azathioprine
- Methotrexate
|
Topics |
- Adult
- Azathioprine
(adverse effects)
- Female
- Humans
- Immunosuppressive Agents
(adverse effects)
- Methotrexate
(therapeutic use)
- Retrospective Studies
- Sarcoidosis
(epidemiology)
- Sweden
|